Abstract
We report the lst case of neuroleptic malignant syndrome occurring in a patient receiving desipramine, a tricyclic antidepressant, with no exposure to neuroleptics. Our case suggests that this syndrome may be caused by a central imbalance between norepinephrine and dopamine, and not by dopamine depletion alone.
MeSH terms
-
Bromocriptine / therapeutic use
-
Dantrolene / therapeutic use
-
Desipramine / adverse effects*
-
Dopamine / metabolism
-
Drug Therapy, Combination
-
Female
-
Humans
-
Middle Aged
-
Neuroleptic Malignant Syndrome / drug therapy
-
Neuroleptic Malignant Syndrome / etiology*
-
Neuroleptic Malignant Syndrome / metabolism
-
Norepinephrine / metabolism
Substances
-
Bromocriptine
-
Dantrolene
-
Desipramine
-
Dopamine
-
Norepinephrine